Crinetics Pharmaceuticals, Inc. (CRNX)
Health Care ยท Pharmaceutical Preparations
Crinetics Pharmaceuticals, Inc. (CRNX) was listed on Nasdaq from July 18, 2018. SentiSense covers Crinetics Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Scott Struthers is its chief executive officer. The company reports 594 employees, and its corporate website is www.crinetics.com.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Latest reported results
Crinetics Pharmaceuticals Inc. reported revenue of $25.1 million for Q2 FY2026, up 2336.3% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 256 institutions reported holding CRNX, with 123.6 million shares worth $4.6 billion in aggregate. The largest reported holders were FMR, Vanguard and BlackRock. Of the 5 largest reported holders, all 5 added shares during the quarter.
More on CRNX
- CRNX sentiment: whether news and social coverage of Crinetics Pharmaceuticals, Inc. leans bullish or bearish, and the stories driving it.
- CRNX ownership: all 256 reporting institutions, plus insider and congressional trades.
- CRNX financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Crinetics Pharmaceuticals, Inc. do?
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
What sector is CRNX in?
SentiSense classifies Crinetics Pharmaceuticals, Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where did CRNX stock trade?
Crinetics Pharmaceuticals, Inc. (CRNX) was listed on Nasdaq from July 18, 2018.
Who is the CEO of Crinetics Pharmaceuticals, Inc.?
Scott Struthers is the chief executive officer of Crinetics Pharmaceuticals, Inc..